BALTIMORE, MD / ACCESSWIRE / October 13, 2020 / AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatment of retinal and other important diseases, will present at the Fall Private Company Showcase hosted by Solebury Trout, BMO and Davis Polk which is being held virtually on October 15, 2020.
Asclepix is scheduled to present on October 15 at 3.40pm EST, with one-on-one meetings to be held throughout the conference. The Presentation will be webcast live and available for replay: https://www.webcaster4.com/Webcast/Page/2408/37749
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email jbalanova@soleburytrout.com
About AsclepiX Therapeutics, Inc.
AsclepiX Therapeutics Inc. is a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular homeostasis that is disrupted in retinal and oncologic diseases. The novel clinical candidate peptides discovered by AsclepiX tap into these naturally existing self-regulating mechanisms, evolved over millions of years, that the body uses to maintain homeostasis and thus restore and maintain health. AXT107, an investigational product and the lead clinical candidate, has a unique mechanism of action that targets two clinically proven pathways of diseases of the retina. The novel self-assembling gel depot that AXT107 forms upon injection into the vitreous, may reduce patient and caregiver burden patients by decreasing the number of treatment injections, potentially to only once every year. AXT107 is poised to enter the clinic in late 2020. Learn more at www.asclepix.com.
Investor contact:
AsclepiX Therapeutics: Julia Balanova, jbalanova@soleburytrout.com 646-378-2936
SOURCE: AsclepiX Therapeutics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/609859/AsclepiX-Therapeutics-to-Present-at-Solebury-Trout-Private-Company-Showcase-on-October-15-2020
Greg Groenke Appointed CEO; Lars Marcher Named Executive ChairmanNEW YORK--(BUSINESS WIRE)--JLL Partners (“JLL” or the…
MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq:…
The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program…
Two Regional Powerhouses to Strengthen Cross-Border Collaboration for a More Resilient and Accessible Healthcare Supply…
Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65 Million in Contingent…
SHANGHAI, June 30, 2025 /PRNewswire/ -- In an era where real-time treatment agility defines competitive…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
